MOG and myeloid sarcoma: Although patients with MS phenotype and MOG-IgG positivity are sometimes regarded as having “atypical manifestations of MOGAD that can mimic MS,” their clinical characteristics (e.g., presence of CSF-restricted OCB, persistence of T2-abnormalities over time, development of progressive disability) and response to MS-targeted disease modifying treatments are more suggestive of a false positive (or true positive but clinically irrelevant) result (146).